Britain is poised to miss out on billions in pharmaceutical R&D investment and access to new medicines unless urgent reforms are made to the NHS medicine rebate system, according to
Britain is poised to miss out on billions in pharmaceutical R&D investment and access to new medicines unless urgent reforms are made to the NHS medicine rebate system, according to






